CHP
DMAC icon

Cable Hill Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Cable Hill Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$5K – 255
2019
Q1 		$5K Buy
+1,000
New +$3.61K ﹤0.01% 600

Other funds holding DMAC

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cable Hill Partners's DMAC Position: Q2 2019 in Review

Cable Hill Partners sold out of DiaMedica Therapeutics (DMAC) in Q2 2019, closing a stake of 1,000 shares — an estimated $5K sold.

Cable Hill Partners first reported a position in DMAC in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 16 funds tracked by Wall St. Rank hold DMAC as of Q2 2019.

  • Cable Hill Partners reported no remaining DiaMedica Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 1,000 DiaMedica Therapeutics shares in Q2 2019, an estimated $5K.
  • Cable Hill Partners first reported a position in DiaMedica Therapeutics in Q1 2019 and held it in 1 quarter.
  • Cable Hill Partners's DiaMedica Therapeutics position peaked at $5K in Q1 2019.
  • 16 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.